omni
aaps
New Tool To Assess Largely Ignored Risk in Pharmaceutical Industry
New Tool To Assess Largely Ignored Risk in Pharmaceutical Industry
A new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body has been developed by researchers at Cardiff University.
Drug Policy: The Year In Review, And The Year Ahead
Drug Policy: The Year In Review, And The Year Ahead
Last year was an unquestionably busy time for health care news of all kinds.
Probe Into Generic Drug Price Fixing Set To Widen
Probe Into Generic Drug Price Fixing Set To Widen
Forty-five states and the Department of Justice are claiming that generic drug prices are fixed, and the alleged collusion may have cost U.S. business and consumers more than $1 billion.
Pharmaceutical Companies Face Harsher Antitrust Compliance Challenges
Pharmaceutical Companies Face Harsher Antitrust Compliance Challenges
On Nov. 16 2017, four months after seeking comments, the National Development and Reform Commission (NDRC) released its Price Conduct Guidelines for Operators of Drugs Prone to Shortages and APIs. These are the first price-related anti-monopoly guideli...
Why Pharma Strategic Planning Reduces Productivity And How To Fix It
Why Pharma Strategic Planning Reduces Productivity And How To Fix It
As is often the case in pharma, Emma Walmsley, the CEO of Glaxo, soon after taking office announced a reorganization of R&D, no doubt the product of a thoughtful strategic plan.